Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22558232
Krejci P, et al. (2012) Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation. PLoS One 7, e35826 22558232
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S33-p - CTNNB1 (human)
Modsite: QQQsyLDsGIHsGAT SwissProt Entrez-Gene
Orthologous residues
CTNNB1 (human): S33‑p, CTNNB1 (mouse): S33‑p, CTNNB1 (rat): S33‑p, CTNNB1 (rabbit): S33‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WNT3A (human) decrease
FGF2 augment treatment-induced decrease

S37-p - CTNNB1 (human)
Modsite: yLDsGIHsGATtTAP SwissProt Entrez-Gene
Orthologous residues
CTNNB1 (human): S37‑p, CTNNB1 (mouse): S37‑p, CTNNB1 (rat): S37‑p, CTNNB1 (rabbit): S37‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WNT3A (human) decrease
FGF2 augment treatment-induced decrease

T41-p - CTNNB1 (human)
Modsite: GIHsGATtTAPsLsG SwissProt Entrez-Gene
Orthologous residues
CTNNB1 (human): T41‑p, CTNNB1 (mouse): T41‑p, CTNNB1 (rat): T41‑p, CTNNB1 (rabbit): T41‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WNT3A (human) decrease
FGF2 augment treatment-induced decrease

Y142-p - CTNNB1 (human)
Modsite: AVVNLINyQDDAELA SwissProt Entrez-Gene
Orthologous residues
CTNNB1 (human): Y142‑p, CTNNB1 (mouse): Y142‑p, CTNNB1 (rat): Y142‑p, CTNNB1 (rabbit): Y142‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  chondrosarcoma
Relevant cell lines - cell types - tissues:  RCS (chondrocyte)
Cellular systems studied:  cell lines
Species studied:  rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE FGFR3 (human)
KINASE FGFR2 (human)
KINASE EGFR (human)
KINASE TrkA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE TrkA (human) transfection of wild-type enzyme
KINASE FGFR3 (human) transfection of wild-type enzyme
KINASE EGFR (human) transfection of wild-type enzyme
KINASE FGFR2 (human) transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF2 increase

S1490-p - LRP6 (human)
Modsite: AILNPPPsPAtERsH SwissProt Entrez-Gene
Orthologous residues
LRP6 (human): S1490‑p, LRP6 (mouse): S1490‑p, LRP6 (rat): L1222‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  chondrosarcoma
Relevant cell lines - cell types - tissues:  293 (epithelial), RCS (chondrocyte)
Cellular systems studied:  cell lines
Species studied:  human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, activation of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WNT3A (human) increase
U0126 WNT3A (human) no effect upon treatment-induced increase
tunicamycin decrease
tunicamycin WNT3A (human) inhibit treatment-induced increase
FGF2 increase
tunicamycin FGF2 no effect upon treatment-induced increase
augment treatment-induced decrease
U0126 FGF2 inhibit treatment-induced increase
SU5402 FGF2 inhibit treatment-induced increase

T1572-p - LRP6 (human)
Modsite: EPVPPPPtPRsQyLs SwissProt Entrez-Gene
Orthologous residues
LRP6 (human): T1572‑p, LRP6 (mouse): T1572‑p, LRP6 (rat):
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, activation of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF2 increase
U0126 FGF2 inhibit treatment-induced increase
SU5402 FGF2 inhibit treatment-induced increase
FGFR2 (human) increase disease-related mutants
FGFR3 (human) increase disease-related mutants